Biocon, India's leading biopharmaceutical company, reported a 153 percent year-on-year (YoY) jump in net profit for the fourth quarter of FY25, led by strong performances in its biosimilars and generics businesses. Consolidated net profit rose to Rs 344 crore, while revenue climbed 15 percent to Rs 4,454 crore on a like-for-like basis.
For the full fiscal year, Biocon posted revenue of Rs 16,470 crore, up 5 percent, and EBITDA of Rs 4,374 crore, with a margin of 27 percent. Net profit for FY25 stood at Rs 1,013 crore, up 30 percent on a like-for-like basis after adjusting for one-time gains.
The company said its Board approved a fundraise of up to Rs 4,500 crore through the issue of securities via qualified institutional placements, rights issue, or other permissible routes, in one or more tranche. The company also said it is evaluating a potential merger of Biocon Biologics with the parent company.
“The Biocon Group ended the year with a strong performance across its businesses,” said Kiran Mazumdar-Shaw, Chairperson of Biocon Group. “FY25 has been a year of consolidation and transition. We are now on a path of accelerating growth with a commitment to innovation, digital augmentation and operational excellence.”
Generics revenue surged 46 percent YoY in Q4FY25 to Rs ₹1,048 crore, driven by U.S. launches of Lenalidomide and Dasatinib. FY25 revenue rose 8% to Rs 3,017 crore. Biosimilars revenue grew 9 percent YoY in Q4Fy25 to Rs 2,463 crore and 15 percent for the full year to Rs 9,017 crore. Four biosimilars crossed $200 million in annual sales, the company said.
Research Services (Syngene) posted Q4 revenue of Rs 1,018 crore, up 11 percent YoY, with full-year revenue at Rs 3,642 crore.
“Our biosimilars continue to build impressive shares in global markets,” said Shreehas Tambe, CEO of Biocon Biologics. “We are well positioned to launch five new products in the next 12–18 months and expand patient access.”
Syngene, Biocon’s contract research arm, crossed Rs 1,000 crore in quarterly revenue for the first time. “The positive momentum that drove Syngene’s return to growth in the latter half of FY25 is expected to continue into FY26,” said Peter Bains, CEO of Syngene.
Biocon Biologics launched its fifth biosimilar, Yesintek (ustekinumab), in the U.S. and Germany, and secured a U.S. market entry date for Yesafili (aflibercept). The company also expanded its GLP-1 portfolio with the UK launch of Liraglutide.
“We remain focused on the strategic expansion of our differentiated GLP-1 portfolio into new markets,” said Siddharth Mittal, CEO of Biocon Ltd. “In FY26, we expect to see a recovery in the API business, aided by cost improvement initiatives and new capacities.”
The board recommended a final dividend of ₹0.50 per share.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
